Back to top
more

Penumbra (PEN)

(Delayed Data from NYSE)

$233.30 USD

233.30
525,994

+4.43 (1.94%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $233.26 -0.04 (-0.02%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 32% (79 out of 250)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

CVS Health (CVS) Retail Arm Continues to Grow Amid Rising Costs

by Zacks Equity Research

CVS Health (CVS) continues to give high priority to digital engagement, after surpassing 50 million unique digital customers in the first quarter.

STERIS (STE) Buys Surgical Instrumentation Platform From BDX

by Zacks Equity Research

STERIS (STE) announces the buyout of surgical instrumentation assets from Becton, Dickinson and Company in a $540 million transaction.

Zimmer Biomet (ZBH) Gains From Procedure Recovery, New Launches

by Zacks Equity Research

Zimmer Biomet (ZBH) is encouraged about the early positive impact of the Hip Insight launch.

SenesTech (SNES) New Alliance to Aid Expansion in South Africa

by Zacks Equity Research

NSPCA is also working on recommending SenesTech's (SNES) ContraPest to private and state entities and to assist with regulatory issues.

Insulet (PODD) Launches the Omnipod 5 AID System in the UK

by Zacks Equity Research

Insulet (PODD) commercializes its revolutionary Omnipod 5 AID System in the United Kingdom.

Here's Why You Should Retain National Vision (EYE) Stock Now

by Zacks Equity Research

Investors continue to remain optimistic about National Vision (EYE) due to the expansion of stores and new investments for the improved optometric experience.

Why You Should Retain Walgreens Boots (WBA) Stock for Now

by Zacks Equity Research

Investors are optimistic about Walgreens Boots (WBA) on a strong focus on strategic priorities.

Neogen (NEOG) Awarded for its Petrifilm Plate Reader Advanced

by Zacks Equity Research

Neogen (NEOG) receives the prestigious 2023 Red Dot Award for the Petrifilm Plate Reader Advanced in Design category.

Here's Why Investors Should Retain Phibro (PAHC) for Now

by Zacks Equity Research

Investors are optimistic about Phibro's (PAHC) diversified offerings and booming vaccine business.

Edwards Lifesciences' (EW) TMTT Sales Aid Amid Margin Woes

by Zacks Equity Research

Edwards Lifesciences (EW) continues to expect the global TAVR opportunity to increase to $10 billion by 2028.

QIAGEN (QGEN) Publishes New Data on QuantiFERON TB Testing

by Zacks Equity Research

The study on QIAGEN's (QGEN) QuantiFERON-TB Gold Plus confirms the crucial role of CD8 T-cells for a broad immune assessment of TB infection.

Walgreens Boots (WBA) Aids Freenome in Early Cancer Detection

by Zacks Equity Research

The collaboration between Walgreens Boots (WBA) and Freenome to advance research based on the early detection of cancer.

ResMed's (RMD) New Buyout Aids Growth Amid Rising Costs

by Zacks Equity Research

ResMed's (RMD) respiratory care business witnesses continued customer uptake of bilevel and other non-invasive ventilator solutions worldwide.

CVS Health (CVS) Invests in Renewable Energy With New Pact

by Zacks Equity Research

CVS Health (CVS) to receive clean, renewable energy through a 12-year agreement with Constellation.

Here's Why Investors Should Retain SmileDirectClub (SDC) Now

by Zacks Equity Research

Meaningful innovations and strategic alliances boost investors' confidence in SmileDirectClub (SDC).

Encompass Health's (EHC) 158th Hospital Opens in Maryland

by Zacks Equity Research

The Rehabilitation Hospital of Bowie is Encompass Health's (EHC) second location in the state of Maryland.

Charles River's (CRL) Improved Volume Aids Amid Margin Woe

by Zacks Equity Research

Charles River (CRL) registers growth in small research models, research model services and the Cell Solutions business.

Here's Why You Should Retain Alcon (ALC) Stock for Now

by Zacks Equity Research

Investors continue to be optimistic about Alcon (ALC) on the impressive performance of the Surgical and Vision Care segments.

Charles River (CRL) Introduces LVV Packaging Plasmids

by Zacks Equity Research

Charles River (CRL) launches packaging plasmids to accelerate and standardize lentiviral vector development.

Globus Medical (GMED) to Gain From NUVA Merger Amid Margin Woe

by Zacks Equity Research

Globus Medical (GMED) continues to make significant progress in launching its prone lateral patient positioning system.

Charles River (CRL) Inks a CDMO Partnership for Bladder Cancer

by Zacks Equity Research

Curigin's oncolytic RNAi gene therapies are set to leverage Charles River's (CRL) expertise in CDMO solutions.

Myriad Genetics' (MYGN) New Pact to Use MRD Testing Platform

by Zacks Equity Research

Myriad Genetics (MYGN) announces research collaboration with MD Anderson on metastatic RCC with its high-definition MRD research testing platform based on whole-genome sequencing.

Abbott (ABT) EPD Sales Gain Traction, Margin Pressure Lingers

by Zacks Equity Research

Abbott (ABT) continues to make good progress in Nutrition, increasing manufacturing production and recovering market share in this business.

LabCorp (LH) Gives Update as Fortrea Spinoff Nears Closure

by Zacks Equity Research

Fortrea is set to comprise Labcorp's (LH) Clinical Development and Commercialization Services businesses.

Inspire (INSP) Gets FDA Nod for Expanded Indication of AHI

by Zacks Equity Research

The FDA approves Inspire's (INSP) application to expand the indication to include patients with AHI up to 100 events per hour.